skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Paclitaxel Trevatide (Code C99461)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Paclitaxel Trevatide

Definition: A peptide-drug conjugate containing the taxane paclitaxel covalently linked to the proprietary 19 amino acid peptide angiopep-2, in a 3:1 ratio, with potential antineoplastic activity. Upon administration, paclitaxel trevatide, via angiopep-2 moiety, binds to LRP-1 (low density lipoprotein receptor-related protein 1), which is highly expressed in blood brain barrier (BBB) and glioma cells. This binding allows the transcytosis of the agent across the BBB and the delivery of the cytotoxic agent paclitaxel. Compared to paclitaxel alone, GRN1005 is able to increase the concentration of paclitaxel in the brain and is also able to specifically deliver paclitaxel to LRP-1-overexpressing tumor cells, both in the brain and in the periphery.

Display Name: Paclitaxel Trevatide

Label: Paclitaxel Trevatide

NCI Thesaurus Code: C99461 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2604058  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Paclitaxel Trevatide

External Source Codes: 
FDA UNII Code 8P77G99D3P
PDQ Closed Trial Search ID 721733
PDQ Open Trial Search ID 721733 (check for NCI PDQ open clinical trial info)
UMLS CUI C2604058

Other Properties:
     Name Value (qualifiers indented underneath)
code C99461
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom